Organisational changes critical to EMA's sustainability, says new report
This article was originally published in SRA
While the European Medicines Agency has proven effective in protecting human and animal health in the European region, the whole medicines authorisation system "is progressively attaining its maximum capacity", says a new report published by the European Commission1,2. Thus, there is an urgent need for the agency to appropriately alter its organisation to ensure its sustainability in the face of novel challenges.
You may also be interested in...
The European Commission is deciding on the terms of reference of an external study, to be completed in 2018, in order to comply with its legal obligation of publishing a general report every 10 years on the experience acquired with various EU marketing authorization procedures for human drugs.
A draft EU guideline explains how disease registries can be used to supplement evidence in the pre-authorization phase and provide infrastructure for post-authorization evidence generation.
Companies are being encouraged to become “early adopters” of the EU Clinical Trials Information System when it goes live in December 2021.